Design and Synthesis of New JAK1 Inhibitors based on Sulfonamide- Triazine Conjugates

Curr Comput Aided Drug Des. 2021;17(7):916-926. doi: 10.2174/1573409916666201224152253.

Abstract

Aims: Design of sulfonamide-triazine derivatives as JAK1 inhibitors.

Background: JAK1 is a kinase involved in different autoimmune diseases. JAK1 inhibitors have shown promising results in treating autoimmune diseases.

Objectives: To design new JAK1 inhibitors based on sulfonamides-triazine conjugates capable of binding interactions comparable to observed interactions anchoring potent crystallographic JAK1 inhibitors.

Methods: The crystallographic structures of 4 diverse nanomolar inhibitors complexed within JAK1 were used to guide the synthesis of new diaminotriazine-sulfonamide-based JAK1 inhibitors.

Results: Nineteen compounds have been prepared, some of which exhibited low micromolar IC50 values against JAK1.

Conclusions: Crystallographic complexes of diverse JAK1 inhibitors were successfully used to guide the synthesis of novel sulfonamide-triazine-based low micromolar JAK1 inhibitors.

Keywords: JAK1 inhibitors; crystallographic complexes.; diamino-triazines; docking; dose-response; sulfonamides.

MeSH terms

  • Molecular Docking Simulation
  • Molecular Structure
  • Structure-Activity Relationship
  • Sulfonamides* / pharmacology
  • Triazines* / pharmacology

Substances

  • Sulfonamides
  • Triazines